Using a cut-off of 2.0 IU/L, FSH demonstrated a sensitivity of 100% and specificity of 98% for distinguishing GCTs from other ovarian tumors, with an area under the ROC curve of 0.99. Here, BRD2 is linked to ovarian neoplasm.